Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

@article{Batist2002MyocetD,
  title={Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy},
  author={G. Batist and J. Barton and P. Chaikin and C. Swenson and L. Welles},
  journal={Expert Opinion on Pharmacotherapy},
  year={2002},
  volume={3},
  pages={1739 - 1751}
}
Doxorubicin, either as a single agent or in combination regimens, is considered to be one of the most active chemotherapeutic agents in the treatment of metastatic breast cancer. However, its clinical utility is limited by a cumulative, dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure. Considerable research has gone into improving the therapeutic index of doxorubicin-based regimens. A new liposomal formulation of doxorubicin (Myocet™, Elan… Expand
Liposomal Doxorubicin
Advantages of liposomal delivery systems for anthracyclines.
Liposome-based approaches to overcome anticancer drug resistance.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 89 REFERENCES
Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison
Liposomal doxorubicin.
Liposomal anthracyclines for breast cancer.
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
  • G. Batist, G. Ramakrishnan, +10 authors L. Lee
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Anthracyclines in breast cancer: therapy and issues of toxicity
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
...
1
2
3
4
5
...